Invitae Corp
NYSE:NVTA
Intrinsic Value
Invitae Corp. engages in the provision of genetic information into mainstream medical practice. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of NVTA.
Whether you're assessing long-term stability or short-term opportunities, Historical Valuation serves as a vital tool to enhance your investment approach, enabling you to make more informed investment decisions.
Sign up
to access Invitae Corp's intrinsic value history.
No restrictions, no limits.
All stocks, all tools.
Look for stocks that have been historically overvalued but are now trading below their intrinsic value.
Avoid stocks that are always undervalued and never reach their intrinsic value.
Find stocks that have historically corrected quickly from being undervalued to reaching their intrinsic value.
Fundamental Analysis
Balance Sheet Decomposition
Invitae Corp
| Current Assets | 451m |
| Cash & Short-Term Investments | 325m |
| Receivables | 85.6m |
| Other Current Assets | 40.5m |
| Non-Current Assets | 1.1B |
| PP&E | 167m |
| Intangibles | 874m |
| Other Non-Current Assets | 31.1m |
| Current Liabilities | 152m |
| Accounts Payable | 23.1m |
| Accrued Liabilities | 115m |
| Other Current Liabilities | 13.6m |
| Non-Current Liabilities | 1.6B |
| Long-Term Debt | 1.4B |
| Other Non-Current Liabilities | 150m |
NVTA Profitability Score
Profitability Due Diligence
Invitae Corp's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
Score
Invitae Corp's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
NVTA Solvency Score
Solvency Due Diligence
Invitae Corp's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Score
Invitae Corp's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NVTA Price Targets Summary
Invitae Corp
According to Wall Street analysts, the average 1-year price target for
NVTA
is 1.73 USD
with a low forecast of 0.51 USD and a high forecast of 4.2 USD.
Ownership
NVTA Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
NVTA Price
Invitae Corp
| Average Annual Return | 28.76% |
| Standard Deviation of Annual Returns | 102.8% |
| Max Drawdown | -99% |
| Market Capitalization | 179m USD |
| Shares Outstanding | 260 675 008 |
| Percentage of Shares Shorted | 16.2% |
Company Profile
Invitae Corp
Country
Industry
Market Cap
Dividend Yield
Description
Invitae Corp. engages in the provision of genetic information into mainstream medical practice. The company is headquartered in San Francisco, California and currently employs 3,000 full-time employees. The company went IPO on 2015-02-12. The firm is engaged in delivering genetic testing services that support a lifetime of patient care from inherited disease diagnoses, to family planning, to proactive health screening to personalized diagnosis, treatment and monitoring of cancer. These tests are delivered through a platform that serves patients, healthcare providers, biopharma companies and other partners, thereby capturing the potential of genetics and helping to expand its use across the healthcare continuum. The company offers Invitae Digital Health, a connected digital health platform that informs health decisions through actionable genomic insights for patients and clinicians. The firm offers genetic testing across multiple clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, personalized oncology, metabolic conditions, and rare diseases.
Sensibly Priced Quality
Significantly Undervalued
Magic Formula
High Growth
